Treatment Guidelines
HCV Treatment Guidelines
EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions
- Details
- Category: HCV Treatment Guidelines
- Published on Wednesday, 09 April 2014 00:00
- Written by Keith Alcorn
The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for HCV genotypes 1, 2, 3, and 4, or simeprevir (Olysio) with pegylated interferon interferon and ribavirin for genotype 1 infection. The WHO guidelines were released to coincide with the 49th International Liver Congress this week in London. New guidelines from the European Association for the Study of the Liver (EASL) will be released on Saturday.
Advances in Hepatitis C Treatment: the Future Is Now [VIDEO]
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 24 March 2014 00:00
- Written by Gregory Fowler
As effective direct-acting antiviral drugs to treat hepatitis C come into widespread use and interferon-free therapy becomes a reality, patients, providers, and payers are now grappling with issues such as who should receive treatment and how to pay for the new medications.
AASLD, IDSA & IAS-USA Announce New Hepatitis C Treatment Guidelines
- Details
- Category: HCV Treatment Guidelines
- Published on Wednesday, 29 January 2014 00:00
- Written by Liz Highleyman
The American Association for the Study of Liver Diseases (AASLD), the Infectious Diseases Society of America (IDSA), and the International Antiviral Society-USA (IAS-USA) this week announced the first new hepatitis C treatment guidelines that include next-generation direct-acting antiviral agents recently approved by the FDA. The guidance is available on a new website, HCVguidelines.org, that will enable frequent updates to reflect emerging data.
CROI 2014/APASL 2014: Merck Combo Suppresses HCV in Monoinfected and Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 March 2014 00:00
- Written by Liz Highleyman
An all-oral combination of the HCV protease inhibitor MK-5172 and the NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in HIV/HCV coinfected patients and high cure rates in people with hepatitis C alone, according to findings from the C-WORTHY study presented at recent conferences.
New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, PrEP
- Details
- Category: HIV Treatment
- Published on Friday, 03 August 2012 00:00
- Written by Liz Highleyman
On the occasion of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, the International Antiviral Society-USA (IAS-USA) released new guidelines recommending that all people diagnosed with HIV should be offered antiretroviral therapy (ART).
More Articles...
- Guidelines Galore: U.S. and EACS Update HIV Recommendations, AASLD Revision Adds New HCV Drugs
- New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, and PrEP
- AASLD Hepatitis C Treatment Guidelines Updated to Include Boceprevir and Telaprevir
- EASL Releases New Hepatitis C Clinical Practice Guidelines
Web Design and Development by